Overview: Hormone refractory prostate cancer

Urology

Volumn 54, Issue 6 SUPPL. 1, 1999, Pages 1-7

  Crawford, E David ^a   Rosenblum, Mark ^b   Ziada, Ali M ^a   Lange, Paul Henry ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DOCETAXEL; ENDOTHELIN A RECEPTOR ANTAGONIST; ERYTHROPOIETIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; FLUTAMIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; GONADORELIN AGONIST; HYDROCORTISONE; KETOCONAZOLE; METHOTREXATE; MITOXANTRONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PRINOMASTAT; STRONTIUM 89; TAXANE DERIVATIVE; VINBLASTINE; VINCRISTINE;

ANEMIA; ANIMAL MODEL; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CLINICAL TRIAL; DRUG INDUCED DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NONHUMAN; PATHOLOGIC FRACTURE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RAT; REVIEW; URETER OBSTRUCTION;

EID: 0032761752     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00447-1     Document Type: Article

References (38)

1. Parker S.L., Tong T., Bolden S., et al. Cancer statistics, 1997. CA Cancer J Clin. 47:1997;5.
2. Wingo P.A., Landis S., Ries L.A.G. An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin. 47:1997;239.
3. Issacs J.T., Coffey D.S. Adaptation vs. selection as the mechanism responsible for relapse of prostate cancer to androgen ablation therapy as studied in the Dunning R-3227-H adenocarcinoma. Cancer Res. 41:1981;5070.
4. Bruchovsky N., Rennie P.S., Coldman A.S., Goldenberg S.L., To M., Lawson D. Effects of androgen withdrawal on stem cell composition of the Shionogi carcinoma. Cancer Res. 50:1990;2275.
5. Crawford E.D., Blumenstein B.A. Proposed substages for metastatic prostate cancer. Urology. 50:(6):1997;1027-1028.
6. Labrie F., Dupont A., Belanger A., et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer a marked improvement in response and survival . J Steroid Biochem. 23:1985;833-842.
7. Schellhammer P.F. Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology. 47:1996;622-628.
8. Blumenstein B.A. Some statistical considerations for the interpretation of trials of combined androgen therapy. Cancer. 72:(suppl 12):1993;3834-3846.
9. Maximum androgen blockade in advanced prostate cancer an overview of 22 randomized trials with 3283 deaths in 5710 patients . Lancet. 346:1995;265-269.
10. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 339:1998;1036-1042.
11. Fair W.R., Heston W.D.W. Overview of cancer biology and principles of oncology. Walsh P.C., Retik A.B., Stamey T.A., Vaughan E.D. Campbell's Urology. 6th ed :1992;1031-1052 WB Saunders, Philadelphia.
12. Isaacs J.T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate. 5:1984;1-7.
13. Byar D.P., Corle D. Hormone therapy for prostate cancer results of the Veterans Administration Cooperative Urological Research Group studies of cancer of the prostate . Natl Cancer Inst Monogr. 7:1988;165-170.
14. Zincke H., Bergstralh E.J., Larson-Keller J.J., et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment evidence for favorable survival in patients with DNA diploid tumors . Cancer. 70:(suppl):1992;311-323.
15. Kramolowski E.V. The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol. 139:1988;1242-1244.
16. Immediate versus deferred treatment for advanced prostatic cancer initial results of the medical research council trial . Br J Urol. 79:1997;235-246.
17. Hillner B.E., McCloud D.G., Crawford E.D., Bennett C.L. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology. 45:1995;633-640.
18. Crawford E.D., Fradet Y., Boccon-Gibod L., Bennett C., Schalken J.A. The role of antiandrogens in hormonal therapy. Contemp Urology. 10:1998;43-57.
19. Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., Sullivan L.D. Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer. 71:1993;2782-2789.
20. Goldenberg S.L., Bruchovsky N., Gleave M.E., Sullivan L.D., Akakura K. Intermittent androgen suppression in the treatment of prostate cancer a preliminary report . Urology. 45:1995;839-845.
21. Eisenberger M.A. Chemotherapy for prostate carcinoma. Natl Cancer Inst Monogr. 7:1988;151-163.
22. Amaato R.J., Ellerhorst J., Bui C., et al. Estramustine and vinblastine for patients with progressive androgen independent adenocarcinoma of the prostate. Urol Oncol. 1:1995;168.
23. Kreis W. Current chemotherapy and future directions in research for the treatment of advanced hormone refractory prostate cancer. Cancer Invest. 13:1995;296.
24. Logothetis CJ, Samuels ML, von Eschenbach AF, et al: Doxorubicin, mitomycin-C and 5-flurouracil in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1 (6): 368-379, 1983.
25. Seidman A.D., Scher H.I., et al. Estramustine and vinblastine use of PSA as a clinical trial end point in hormone refractory prostate cancer . J Urol. 147:1992;931.
26. Roth B.J., Yeap B.Y., Wilding G., et al. Taxol in advanced, hormone-refractory carcinoma of the prostate a phase II trial of the Eastern Oncology Group . Cancer. 72:(8):1993;2457-2460.
27. Hudes G.R., Nathan F., Khater C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. Clin Oncol. 15:(9):1997;3156-3163.
28. Smith D.C., Pienta K.J. Paclitaxel in the treatment of hormone refractory prostate cancer. Semin Oncol. 261:(1 suppl 2):1999;109-111.
29. Cross M., Dexter T.M. Growth factors in development, transformation, and tumorigenesis. Cell. 64:1991;271.
30. Stancovski I., Sela M., Yarden Y. Molecular and clinical aspects of the neu/erbB-2 receptor tyrosine kinase. Cancer Treat Res. 71:1994;161.
31. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the Her-2/neu protooncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
32. Ross J.S., Sheehan C., Hayner-Buchnan A., et al. Her-2/neu gene amplification status in prostate cancer by fluorescense in situ hybridization. Hum Pathol. 28:1998;827-833.
33. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
34. Nelson J.B., Chan-Tack K., Hedican S.P., et al. Endothelin production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 56:1996;663-668.
35. Eckhardt S.G., Pluda J.M. Development of angiogenesis inhibitors for cancer therapy. Invest New Drugs. 15:(1):1997;1-3.
36. Nguyen N.M., Lehr J.E., Pienta K.J. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res. 13:(6A0):1993;2143-2147.
37. Yamaoka M., Yamamoto T., Ikeyama S., Sudo K., Fujita T. Angiogenesis inhibitor TNP-470 potentially inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. 53:(21):1993;5233-5236.
38. Smith J.A. Jr, Soloway M.S., Young M.J. Complications of advanced prostate cancer. Urology. 54:(suppl 6A):1999;8-14.